Gyre Therapeutics, Inc. (GYRE) Free cash flow 2016–2025
Gyre Therapeutics, Inc. (GYRE) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$180,000FY2025 · since FY2016: -$18.9M → -$180,000
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$180,000 | +97.0% |
| FY2024 | -$6.0M | -134.3% |
| FY2023 | $17.4M | +205.3% |
| FY2022 | $5.7M | +106.7% |
| FY2021 | -$84.6M | — |
| FY2019 | -$43.7M | -51.0% |
| FY2018 | -$28.9M | -44.9% |
| FY2017 | -$20.0M | -5.4% |
| FY2016 | -$18.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More GYRE financial trends
GYRE RevenueGYRE Net incomeGYRE Net marginGYRE Gross profitGYRE Gross marginGYRE Operating incomeGYRE Operating marginGYRE Operating cash flowGYRE Capital expendituresGYRE Return on equityGYRE Stock buybacksGYRE Dividends paidGYRE Total assetsGYRE Total liabilitiesGYRE Shareholders’ equityGYRE overview →